Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 03/23/2020
Short Title (70 char) Vibrant K9. Oak Hills, CA. Sample Analysis issued 03/23/2020
FEI Number 3016619230
Firm Name Vibrant K9
Record Type Sample Analysis
State CA
Establishment Type Pet Food Manufactu
Similar Posts
Guidance: Borderline products: medical devices and other products
How the MHRA makes decisions on whether a borderline product is a medical device and whether medical devices regulations should apply.
Decision: Parallel import licences granted in 2025
Parallel import licences granted in 2025.
FDA Clinical Trials Training Modules
This training represents regulatory intelligence that sets global standards for clinical research. The content reflects current FDA thinking, emerging guidance, and real-world regulatory experience, providing participants with the most reliable and up-to-date information available.October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee – 10/10/2024
The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the treatment of Barth Syndrome.Regulation of AI in Healthcare
The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulation of AI in Healthcare.
FDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)
The FDA has received reports of immune effector cell-associated enterocolitis (IEC-EC) in patients who received treatment with CARVYKTI.